semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Headache Aneurysm Endovascular Procedures patients with unruptured intracranial aneurysms patients over 20 years old patients who can communicate with each other patients who agreed to this study (with informed consent)  patients with recurrent aneurysms after coiling or clipping patients with allergic reaction to antiplatelets patients with high risks of hemorrhage patients with coagulopathy patients with thrombocytopenia (<100,000/mm3) patients with liver disease (> 100 of aspartate aminotransferase or alanine aminotransferase) patients with renal disease (> 2mg/dL of serum creatinine)\ patients with uncontrolled heart failure or angina patients with malignant tumor pregnant patients
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Migraine Without Aura Migraine With Aura Subjects age 18-75 years old. 2. Subjects meet the ICHD-3 diagnostic for migraine with or without aura 3. Subjects report 2-8 migraine attacks per month. 4. Stable migraine preventive medications in the last two months prior to recruitment (No change in usage or dosage). 5. Subjects must be able and willing to comply with the protocol 6. Subjects must be able and willing to provide written informed consent  Subject has other significant pain, medical or psychologic problems that in the opinion of the investigator may confound the study assessments 2. Subject has an implanted electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator). 3. Subject has known uncontrolled epilepsy. 4. Any use of Cannabis including medical use. 5. Subject has >10 headache days per month. 6. Subject has undergone nerve block (occipital or other) in the head or neck within the last 2 weeks. 7. Subject is participating in any other clinical study. 8. The subject does not have the basic cognitive and motor skills needed to operate a smartphone. 9. Pregnant, or trying to get pregnant 10. Subject is experiencing a menstrually related migraine 11. Received OnabotulinumtoxinA or any botulinum toxin injections for migraine within the previous month 12. Received parenteral infusions for migraine within the previous 2 weeks. 13. Subject participated in a previous study with the Nerivio Migra 1 device
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Migraine Males and females Ages of 18 to 65 years old. 2. History of episodic or chronic migraine with or without aura meeting the diagnostic listed in ICHD (International Classification of Headache Disorders)-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction). 3. Capable to corporate with the study protocol and to sign an informed consent  Patients having received Botox treatment in the head region in the prior 4 months. 2. Patients having received supraorbital or occipital nerve blocks in the prior 4 months. 3. History of Medication Overuse Headache. 4. Patients using opioid medication. 5. Allodynia: intolerance to supraorbital and/or occipital neurostimulation that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 10 minutes of neurostimulation). 6. Implanted metal or electrical devices in the head (not including dental implants). 7. Patient having had a previous experience with the Relievion™ device. 8. Patients who have concomitant epilepsy. 9. History of neurosurgical interventions. 10. Patients with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps. 11. History of drug abuse or alcoholism. 12. Participation in current clinical study or participated in a clinical study within 3 months prior to this study. 13. Skin lesion or inflammation at the region of the stimulating electrodes. 14. Personality or somatoform disorder. 15. Pregnancy or Lactation. 16. Women with child bearing potential without medically acceptable method of contraception. 17. History of cerebrovascular event. 18. Subjects with recent brain or facial trauma (occurred less than 3 months prior to this study). 19. Patients using Cannabis 20. Patients with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bilateral Cataract Bilateral cataract Indication for bilateral cataract surgery Expected uncomplicated surgery  Inability to comply with study procedures or to complete follow-up / Dutch questionnaires Non-routine cataract surgery Cognitive or behavioural conditions that might interfere with surgery Cataract surgery with premium IOL implantation Conditions that increase the risk of endophthalmitis (e.g. current ocular/adnexal/periocular infections, immune-compromised, iodine allergy) Factors that increase the risk of refractive surprise (e.g. axial lengths <21mm or >27mm, difference between eyes of >1.5mm, abnormal keratometry readings, previous refractive surgery) Conditions that increase the risk of corneal edema Factors that increase the risk of complicated surgery (e.g. previous surgery, trauma, anatomical abnormalities) Sight-threatening comorbidity, Glaucoma or IOP > 24mmHg, Uveitis, Diabetes with diabetic retinopathy and macular edema
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain Injuries Age ≥ 18 years' old Patients admitted in a ICU for a central neurological pathology, listed as follows, with estimated or clinically evaluated Glasgow Coma Score ≤12 before endo-tracheal intubation, with anomaly on brain CT-scan and requiring effective invasive mechanical ventilation ≥ 24 hours are eligible to the study Traumatic Brain Injury Aneurysmal Subarachnoid haemorrhage Intra-Cranial Haemorrhage Ischemic Stroke Central Nervous System Infection (Abscess, Empyema, Meningitides, Encephalitis…) Brain Tumour Patient with an attempt of extubation and/or performance of a tracheostomy  Patients < 18 years' old Patients with ongoing pregnancy Patients with spine cord injury above T4 Resuscitated cardiac arrest Withdrawal of Life-Sustaining Treatment (WLST) in the first 24 hours
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Migraine able and interested in participating to the present research project, as proved by signed Informed consent; 2. 18-65 years of age; 3. Italian mother tongue; 4. diagnosis of chronic migraine according to the International Classification of Headache Disorders. Thus, presenting specific features (i.e., unilateral and pulsating pain of moderate or severe intensity, which is aggravated or precipitated by routine physical activities and is combined with nausea and/or vomiting, photophobia, and phonophobia) and migraine headache on ≥ 15 days per month; 5. headache chronicity for a minimum of 1 year and pattern of headache symptoms stable for a period of at least 6 months; 6. no pharmacological therapy or dietary supplements use for chronic migraine OR pharmacological therapy/dietary supplement use for chronic migraine stable since at least 3 months; 7. psychotropic medication allowed only if stable since at least three months  diagnosis of medication overuse headache; 2. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders (DSM) 5th edition as diagnosed via the MINI International Neuropsychiatric Interview; 3. co-occurrence of chronic unstable medical conditions; 4. being pregnant or lactating; 5. under exogeneous hormones treatment (i.e., hormonal contraceptives, postmenopausal hormone therapy); 6. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  New Daily Persistent Headache (NDPH) Patients meeting clinical International Classification of Headache Disorders (ICHD-3 )classification for NDPH 2) Age 10-17 years, all sexes, races, and ethnicities 3) English speaking 4) Able to wean off headache prophylactic medication 2 weeks prior to start of Naltrexone trial (patient will still be able to use abortive medication throughout the duration of the study) 5) On stable psychotropic medication for mild anxiety and/or mood disturbance for 2 weeks -  Children and adolescents with significant chronic medical illness: Central Nervous systen (secondary headache disorder other than mild traumatic brain injury); Cardiac, Pulmonary other than stable asthma, Metabolic, Renal, Hepatic 2) Significant psychiatric disorder, such as major depression, somatization disorder, and psychosis 3) Pregnancy 4) Intellectual delay or cognitive limitations precluding completion of questionnaires or following instructions. -
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 8.0-999.0,  Cancer a) Male and female subjects, at least 8 years of age, prescribed chemotherapy for cancer. (NOTE: Only non-pregnant females are eligible). University of Rochester will enroll young adults (i.e., 21-39 years) and adults (i.e., 40 years and older). RPCI will enroll adolescents (i.e., 8-20 years) and young adults (i.e., 21-39 years). b) Scheduled to receive two or more cycles of chemotherapy. (NOTE: Subjects may have already started chemotherapy, but must have at least three chemotherapy cycles remaining in their current prescribed course.) c) Day 1 of each chemotherapy cycle must be separated from Day 1 of the next chemotherapy cycle by at least 10 days. d) All cancer types and chemotherapy regimens are eligible. (NOTE: Monoclonal antibody therapies are allowed if administered in combination with chemotherapy). e) The chemotherapy regimen must be the same regimen for all study cycles. For example, if a subject with breast cancer was prescribed TAC for Study Cycle 1, the subject must receive TAC for Study Cycles 2 and 3. f) Any number of chemotherapy administrations per week during a chemotherapy treatment cycle is allowed. g) Subjects must agree to discontinue their current use of aromatherapy for symptom management during the course of the study. They must solely use the jojoba and aromatherapy inhalers provided by the study during the course of the study. h) Subjects must be able to read and understand English, as well as provide informed consent in order to participate in this study  a) Subjects < 8 years old are not eligible for participation in this study. b) Pregnant females are ineligible for the study because pregnancy is a contraindication for chemotherapy and exposure to essentials oils. c) Subjects with more than six weeks between chemotherapy treatment cycles are not eligible. d) Concurrent radiation therapy or interferon treatment is not allowed. e) Subjects with any known allergy to ginger, lavender, orange, citrus of any kind, jojoba, or essential oils are not eligible
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Headache, Migraine Migraine Migraine Disorders Headache Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders, 3rd Edition (beta) (ICHD-3b) Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 8 and ≤ 28 PedMIDAS: PedMIDAS Disability Score > 10, indicating at least mild disruption in daily activities and < 140, indicating extreme disability that may require more comprehensive, multi-component therapy English speaking: able to complete interviews and questionnaires in English  Continuous migraine defined as an unrelenting headache for a 28 day period Weight less than 30 kg or greater than 120 kg, or weight/size incompatible with magnetic resonance imaging (MRI) scanner Must agree not to take non-specific acute medication, such as nonsteroidal anti-inflammatory drugs (NSAIDS) (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month No current prophylactic anti-migraine medication within a period equivalent to < 5 half-lives of that medication before entering the screening phase, and agree to not begin a migraine prevention medication during the study period Current use of the following medications/products: opioids, antipsychotics, antimanics, barbiturates, benzodiazepines, muscle relaxants, sedatives, tramadol, nutraceuticals Known history of allergic reaction or anaphylaxis to amitriptyline Abnormal findings on electrocardiogram (ECG) at baseline, particularly lengthening of the QT interval ≥ 450 msec Orthodontic braces, metallic or electronic implants, or other metal objects in the body which obscure or interfere with the MRI, or pose a risk from heating, movement, or malfunction in the MRI environment Claustrophobia Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)
Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Migraine With Aura Migraine Without Aura Allodynia History of migraine with or without aura for at least 3 years, based on the International Classification of Headache disorders Two or more migraine attacks per month on average during the year prior to enrollment Ability to give written consent to enrollment  Fifteen or more headache days per month, on average Aspirin or NSAID induced asthma or allergy Sulfa allergy Any woman who is pregnant or lactacting History of any of the following: Coronary artery bypass surgery, heart attack, angina, stroke, serious gastrointestinal bleeding, peptic ulcer disease, and/or chronic kidney disease Medical Conditions requiring the use of diuretics or daily anticoagulants Severe uncontrolled medical problems or medications that may influence measurements